

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 1 of 14

**PURPOSE:**

The intent of this clinical policy is to provide coverage for benefits available related to the COVID-19 Pandemic.

Unless otherwise stated, this policy is in effect for the duration of the emergency period as declared by the U.S. Secretary of Health and Human Services on January 31, 2020 due to the national public health emergency resulting from the 2019 novel coronavirus. This emergency period began on January 27, 2020 and continues as long as it is continuously extended by the HHS secretary.

**POLICY:**

Aspirus Health Plan waives cost sharing for all groups for the following services, when received from participating and non-participating providers, for the duration of the emergency period as declared by the U.S. Secretary of Health and Human Services

- Centers for Disease Control (CDC) recommended and FDA-approved testing for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID-19; and
- The related office, urgent care, emergency room or telehealth visit which resulted in COVID-19 testing, but only to the extent that such visit is related to the evaluation for and administration of COVID-19 testing; and
- Additional items or services furnished to the member during a visit that results in an order for, or administration of, a COVID-19 test, but only to the extent that the item or service relates to the furnishing or administration of the test or to the evaluation of the member for purposes of determining the need of the member for the product. Examples include testing such as CBC, influenza or strep testing.
- FDA-approved or emergency use authorization (EUA) Coronavirus (COVID-19) vaccination and administration

Aspirus Health Plan waives cost sharing for fully-insured plans for the following services, when received from participating providers

- Administration of an FDA-approved or emergency use authorization (EUA) outpatient monoclonal antibody for COVID infection for the duration of the emergency period as declared by the U.S. Secretary of Health and Human Services (the monoclonal antibody drug is covered by the manufacturer)

Unless otherwise stated, this policy is intended to comply with the Families First Coronavirus Response Act (FFCRA) (H.R. 6201) and applies to all individual and group health plans.

Benefits must be available for health care services. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration.

**EXCLUSIONS (not limited to):**

Refer to member's Certificate of Coverage or Summary Plan Description

CPT 99072 Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease is not covered.

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 2 of 14

HCPCS S8301 Infection control supplies, not otherwise specified

**CODING:**

CPT® or HCPCS

**COVID-19 Testing**

86328 Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

86408 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]); screen

86409 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]); titer

86413 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-10]) antibody, quantitative

86769 Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

87426 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])

87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B

87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique

87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique

87637 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique

87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

0202U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 3 of 14

0223U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected

0224U Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed

0225U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 21 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected

0240U Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected

0241U Infections disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected

C9803 Hospital outpatient clinical visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source

D0606 Molecular testing for a public health related pathogen, including coronavirus

G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source

G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any source

U0001 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel

This code is only to be used for the tests developed by the Centers for Disease Control and Prevention (CDC)

U0002 nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC

Reported by laboratories performing non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19)

U0003 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R

U0004 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 4 of 14

U0005 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoC-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection

**COVID-19 Monoclonal Antibodies and Administration**

Q0240 Injection, casirivimab and imdevimab, 600 mg

Q0243 Injection, casirivimab and imdevimab, 2400 mg

Q0244 Injection, casirivimab and imdevimab, 1200 mg

M0240 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses

M0241 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses

M0243 Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring

M0244 Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

Q0245 Injection, bamlanivimab and etesevimab, 2100 mg

M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring

M0246 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

Q0249 Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg

M0249 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose

M0250 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 5 of 14

J0248 Injection, remdesivir, 1mg (Veklury)

**Vaccination and Administration**

- Pfizer-BioNTech COVID-19 vaccine and administration

91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use

91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

91315 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

91317 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

0001A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose

0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose

0003A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose

0004A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose



<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 6 of 14

0051A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

0052A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

0053A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

0054A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose

0071A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

0072A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

0073A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

0074A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose

0081A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

0082A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

0083A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

0124A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose

0154A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 7 of 14

protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose

0173A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose

D1701 Pfizer-BioNTech Covid-19 vaccine administration - first dose SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 1

D1702 Pfizer-BioNTech Covid-19 vaccine administration - second dose SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 2

- Moderna COVID-19 vaccine and administration

91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use

91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use

91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use

91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg/0.25 mL dosage, for intramuscular use

91313 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use

91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use

91316 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use

0011A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose

0012A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 8 of 14

0013A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

0064A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage; booster dose

0091A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose

0092A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose

0093A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose

0094A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose

0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose

0112A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose

0113A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose

0134A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose

0144A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose

0164A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose

D1703 Moderna Covid-19 vaccine administration - first dose SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 1



<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 9 of 14

D1704 Moderna Covid-19 vaccine administration - second dose SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 2

- Janssen COVID-19 vaccine and administration  
91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage, for intramuscular use

0031A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage, single dose

0034A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5mL dosage, booster dose

D1707 Janssen Covid-19 vaccine administration SARSCOV2 COVID-19 vac ad26 5x10<sup>10</sup> VP/0.5ml IM single dose

- Novavax COVID-19 vaccine and administration  
91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL disease, for intramuscular use

0041A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose

0042A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; second dose

0044A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose

M0201 Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home

**Other**

C9507 Fresh frozen plasma, high titer COVID-19 convalescent, frozen within 8 hours of collection, each unit

J3490 Unclassified Drug (when used for Kineret [anakinra])

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 10 of 14

ICD-10 Diagnosis Code Descriptions

G44.201	Tension-type headache, unspecified, intractable
G44.209	Tension-type headache, unspecified, not intractable
G44.211	Episodic tension-type headache, intractable
G44.219	Episodic tension-type headache, not intractable
G44.59	Other complicated headache syndrome
G44.83	Primary cough headache
G44.84	Primary exertional headache
G44.85	Primary stabbing headache
G44.89	Other headache syndrome
G93.3	Postviral fatigue syndrome
J00	Acute nasopharyngitis [common cold] (acute rhinitis; acute coryza; infective rhinitis; nasopharyngitis, NOS)
J02.8	Acute pharyngitis due to other specified organisms
J02.9	Acute pharyngitis, unspecified (pharyngitis, NOS; sore throat, NOS)
J06.0	Acute laryngopharyngitis
J06.9	Acute upper respiratory infection, unspecified
J12.81	Pneumonia due to SARS-associated coronavirus
J12.82	Pneumonia due to coronavirus disease
J12.89	Other viral pneumonia
J20.8	Acute bronchitis due to other specified organisms
J22	Unspecified acute lower respiratory infection
J40	Bronchitis, not specified as acute or chronic
J80	Acute respiratory distress syndrome
J96.00	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia
J96.01	Acute respiratory failure with hypoxia
J96.02	Acute respiratory failure with hypercapnia
J98.8	Other specified respiratory disorders
M35.81	Multisystem inflammatory syndrome
M35.89	Other specified systemic involvement of connective tissue
M54.5	Low back pain
M54.9	Dorsalgia, unspecified (backache, NOS; back pain, NOS)
M62.81	Muscle weakness (generalized)
M62.838	Other muscle spasm
M79.10	Myalgia, unspecified site (myofascial pain syndrome)
M79.11	Myalgia of mastication muscle
M79.12	Myalgia of auxiliary muscles, head and neck
M79.18	Myalgia, other site
M79.89	Other specified soft tissue disorders (polyalgia)

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 11 of 14

M79.9 Soft tissue disorder, unspecified  
P35.8 Other congenital viral diseases  
R05 Cough  
R06.02 Shortness of breath  
R06.09 Other forms of dyspnea  
R06.1 Stridor  
R06.2 Wheezing  
R06.3 Periodic breathing  
R06.4 Hyperventilation  
R06.82 Tachypnea, not elsewhere classified  
R06.89 Other abnormalities of breathing  
R06.9 Unspecified abnormalities of breathing  
R07.0 Pain in throat  
R07.89 Other chest pain  
R09.2 Respiratory arrest  
R09.81 Nasal congestion  
R09.82 Postnasal drip  
R10.10 Upper abdominal pain, unspecified  
R10.11 Right upper quadrant pain  
R10.12 Left upper quadrant pain  
R10.13 Epigastric pain  
R10.30 Lower abdominal pain, unspecified  
R10.31 Right lower quadrant pain  
R10.32 Left lower quadrant pain  
R10.33 Periumbilical pain  
R10.84 Generalized abdominal pain  
R10.9 Unspecified abdominal pain  
R11.0 Nausea  
R11.10 Vomiting, unspecified  
R11.11 Vomiting without nausea  
R11.12 Projectile vomiting  
R11.2 Nausea with vomiting, unspecified  
R19.7 Diarrhea, unspecified  
R19.8 Other specified symptoms and signs involving the digestive system and abdomen  
R23.0 Flushing, excessive blushing  
R25.2 Cramp and spasm  
R43.0 Anosmia  
R43.1 Parosmia

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 12 of 14

- R43.2 Parageusia
- R43.8 Other disturbances of smell and taste (mixed disturbance of smell and taste)
- R43.9 Unspecified disturbances of smell and taste
- R50.9 Fever, unspecified
- R51 Headache (facial pain NOS)
- R52 Pain, unspecified (acute or generalized pain, NOS)
- R53.1 Weakness
- R53.81 Other malaise (malaise, NOS; debility NOS; general physical deterioration)
- R53.83 Other fatigue (fatigue, NOS; lack of energy; lethargy; tiredness)
- R61 Generalized hyperhidrosis, excessive sweating, night sweats, secondary hyperhidrosis
- R68.83 Chills (without fever)
- U07.1 Other coronavirus as the cause of diseases classified elsewhere
- U099 Post-COVID-19 condition, unspecified
- Z03.818 Encounter for observation for suspected exposure to other biological agents ruled out
- Z11.52 Encounter for screening for COVID-19
- Z11.59 Encounter for screening for other viral diseases
- Z20.822 Contact with and (suspected) exposure to COVID-19
- Z20.828 Contact with and (suspected) exposure to other viral communicable diseases
- Z86.16 Personal history of COVID-19
- Z86.19 Personal history of other infectious and parasitic diseases

General ICD-10-CM Coding Guidelines

- If the provider documents “suspected”, “possible” or “probable” COVID-19, do not assign code U07.1; assign a code(s) explaining the reason for encounter (such as fever, or Z20.828)
- Note: Diagnosis code B34.2, Coronavirus infection, unspecified, would in generally not be appropriate for the COVID-19, because the cases have universally been respiratory in nature, so the site would not be “unspecified”

ICD-10-CM Official Guidelines for Coding and Reporting  
FY 2021 (October 1, 2020 - September 30, 2021)

The following coding guidance has been developed by CDC and approved by the four organizations that make up the Cooperating Parties: the National Center for Health Statistics, the American Health Information Management Association, the American Hospital Association, and the Centers for Medicare & Medicaid Services.

- J82.89 plus U07.1 = pneumonia confirmed due to COVID-19
- J20.8 plus U07.1 = acute bronchitis confirmed due to COVID-19
- J22 plus U07.1 = COVID-19 documented as being associated with a lower respiratory infection, not otherwise specified (NOS), or an acute respiratory infection, NOS
- J98.8 plus U07.1 = COVID-19 documented as being associated with a respiratory infection, NOS
- J80 plus U07.1 = ARDS (acute respiratory distress syndrome) due to COVID-19
- Z03.818 = concern about a possible exposure to COVID-19, but this ruled out after evaluation
- Z20.828 = actual exposure to someone who is confirmed to have COVID-19

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 13 of 14

Acute respiratory failure

For acute respiratory failure due to COVID-19, assign code U07.1, and code J96.0-, Acute respiratory failure.

Z01.84 Encounter for antibody response examination

Encounter for antibody testing

For an encounter for antibody testing that is not being performed to confirm a current COVID-19 infection, nor is a follow-up test after resolution of COVID-19, assign Z01.84, Encounter for antibody response examination.

Z09 Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm

Follow-up visits after COVID-19 infection has resolved

For individuals who previously had COVID-19 and are being seen for follow-up evaluation, and COVID-19 test results are negative, assign codes Z09, Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm, and Z86.19, Personal history of other infectious and parasitic diseases.

Z38.00- Z38. 8 Liveborn infants according to place of birth and type of delivery

COVID-19 Infection in Newborn

For a newborn that tests positive for COVID-19, assign code U07.1, COVID-19, and the appropriate codes for associated manifestation(s) in neonates/newborns in the absence of documentation indicating a specific type of transmission. When coding the birth episode in a newborn record, the appropriate code from category Z38, Liveborn infants according to place of birth and type of delivery, should be assigned as the principal diagnosis.

For a newborn that tests positive for COVID-19 and the provider documents the condition was contracted in utero or during the birth process, assign codes P35.8, Other congenital viral diseases, and U07.1, COVID-19.



<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 02/02/23
<b>Approved by:</b> Chief Medical Officer	<b>Date Approved:</b> 02/01/23
<b>Clinical Policy Document:</b> Special Coverage for the COVID-19 Pandemic	<b>Replaces Effective Clinical Policy Dated:</b> 12/05/22
<b>Reference #:</b> MP/C016	<b>Page:</b> 14 of 14

**REFERENCES:**

1. Integrated Healthcare Services Process Manual: UR015 Use of Medical Policy and Criteria
2. Clinical Policy: MP/C009 Coverage Determination Guidelines
3. Families First Coronavirus Response Act H.R. 6201. Retrieved from <https://www.congress.gov/bill/116th-congress/house-bill/6201/text>. Accessed 03-03-21.
4. FAQs About Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation Retrieved from: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs> Accessed 01-24-22.
5. ICD-10-CM Official Guidelines for Coding and Reporting FY 2021 (October 1, 2020 - September 30, 2021). Retrieved from: <https://www.cdc.gov/nchs/data/icd/10cmguidelines-FY2021.pdf> Accessed 03-03-21.

**DOCUMENT HISTORY:**

<b>Created Date:</b> 03/03/21
<b>Reviewed Date:</b> 03/03/22, 12/14/22
<b>Revised Date:</b> 03/15/21, 04/20/21, 04/26/21, 08/23/21, 10/26/21, 12/20/21, 02/02/22, 03/01/22, 04/18/22, 05/26/22, 07/07/22, 09/23/22, 10/20/22, 12/05/22, 12/14/22, 02/01/23